NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...

Here are the key developments on the 1,051st day of Russia’s full-scale invasion of Ukraine. European champions Real Madrid crush Mallorca 3-0 and will now play archrival Barcelona in the ...